In our study, patients with CDM had higher rates of negative myositis-specific autoantibodies and anti-NXP2 antibodies than those with CADM, and patients with CADM had higher rates of anti-MDA5 antibodies than those with CDM. Here, MORC3 is linked to clinically amyopathic dermatomyositis.